Theraclion S.A.
ALTHE.PA · PAR
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.02 | 0.07 | 0.08 |
| FCF Yield | -9.50% | -9.32% | 0.00% | -5.67% |
| EV / EBITDA | -4.31 | -5.20 | -7.29 | -6.89 |
| Quality | ||||
| ROIC | -30.43% | -22.32% | 0.12% | -18.54% |
| Gross Margin | -1,039.28% | -708.37% | -49.28% | -267.38% |
| Cash Conversion Ratio | 1.40 | 0.52 | 0.64 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.11% | -9.07% | -7.84% | -13.53% |
| Free Cash Flow Growth | 6.23% | 0.00% | 100.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.99 | 0.82 | 3.60 | 2.40 |
| Interest Coverage | -296.67 | -265.07 | 2.07 | -48.92 |
| Efficiency | ||||
| Inventory Turnover | 2.09 | 1.13 | 0.43 | 1.20 |
| Cash Conversion Cycle | 117.20 | 678.76 | 611.44 | 167.48 |